Home
About
Who We Are
Mission
Values
Science & Pipeline
Patients
Leadership
Investors & Media
Overview
Press Releases
Events
Publications / Presentations
Financial Information
Corporate Governance
Stock Information
Investor Resources
Careers
Contact Us
LinkedIn
Privacy
Terms of Use
Kinnate is exploring strategic alternatives for is exarafenib (KIN 2787) as a monotherapy agent.
On April 3, 2024, XOMA completed its acquisition of Kinnate.
Visit XOMA.com
CLOSE
